<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772718</url>
  </required_header>
  <id_info>
    <org_study_id>X358603</org_study_id>
    <nct_id>NCT02772718</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery</brief_title>
  <acronym>XOMA 358</acronym>
  <official_title>An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in&#xD;
      patients with hypoglycemia after gastric bypass surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single dose Part 1 and Multiple dose Part 2 - Incidence of treatment-emergent adverse events -</measure>
    <time_frame>42 days</time_frame>
    <description>Safety assessed by treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose Part 1 - Change from baseline in glucose levels</measure>
    <time_frame>Baseline and 22 days</time_frame>
    <description>Glucose measured using a continuous glucose monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose Part 1 - Blood glucose levels</measure>
    <time_frame>Daily through Day 11 and at Day 22</time_frame>
    <description>Assessment of blood glucose with a bedside meter at multiple time points specified in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple dose Part 2 - Change from baseline of duration of glucose by CGM at various levels as specified in the protocol</measure>
    <time_frame>28 days</time_frame>
    <description>Glucose measured by continuous glucose monitoring every 5 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple dose Part 2 - Change from baseline of number of episodes and percent of episodes of hypoglycemia per day with glucose by CGM at various levels as defined in the protocol</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Part 1 - single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A, B, and C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XOMA 358 single dose level A</intervention_name>
    <description>XOMA 358 single dose level A administered by intravenous infusion</description>
    <arm_group_label>Part 1 - single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XOMA 358 single dose level B</intervention_name>
    <description>XOMA 358 single dose level B administered by an intravenous infusion</description>
    <arm_group_label>Part 1 - single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XOMA 358 single dose level C</intervention_name>
    <description>XOMA 358 single dose level C administered by an intravenous infusion</description>
    <arm_group_label>Part 1 - single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XOMA 358 multiple dose level 1</intervention_name>
    <description>XOMA 358 multiple dose level 1 administered by an intravenous infusion</description>
    <arm_group_label>Part 2 - multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged at least 18 years of age&#xD;
&#xD;
          -  Body Mass Index &lt; 35 kg/m2 at baseline, unless discussed with Medical Monitor and&#xD;
             patients with higher body mass index do not have significant medical co-morbidities&#xD;
             that would confound ability to assess safety and efficacy of study drug.&#xD;
&#xD;
          -  Received gastric bypass surgery more than 1 year before dosing&#xD;
&#xD;
          -  Occurrence of postprandial hypoglycemia (blood glucose less than 60mg/dL) during the&#xD;
             Baseline provocation assessments and/or by continuous glucose monitoring, as defined&#xD;
             in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes&#xD;
&#xD;
          -  Planned use of the following medications on or after Day -3 (Part 1):&#xD;
&#xD;
               -  Any agent for hypoglycemia, such as diazoxide or octreotide&#xD;
&#xD;
               -  Antihyperglycemic agents, including subcutaneous insulin therapy, sulfonylureas,&#xD;
                  SGLT2 inhibitors, and GLP-1 agonists&#xD;
&#xD;
               -  Systemic glucocorticoids or Î² agonists that may affect glucose metabolism&#xD;
&#xD;
               -  Long-acting somatostatin analogs or glucose-affecting medications&#xD;
&#xD;
          -  During Part 2, the following therapies are prohibited as specified below:&#xD;
&#xD;
               -  Tramadol and any other medications not used in the treatment of post-bariatric&#xD;
                  surgery hypoglycemia that may cause hypoglycemia or fluctuations in blood glucose&#xD;
                  levels.&#xD;
&#xD;
               -  Acetaminophen-containing products during periods of continuous glucose&#xD;
                  monitoring.&#xD;
&#xD;
        Medications such as tramadol may cause hypoglycemia or fluctuations in blood glucose levels&#xD;
        and, as such, use of such medications is subject to the restrictions as described above&#xD;
        during the study. Acetaminophen can interfere with the accuracy of the glucose sensor of&#xD;
        the continuous glucose monitoring system and is, therefore, prohibited during continuous&#xD;
        glucose monitoring.&#xD;
&#xD;
          -  Major general surgery within 3 months before study entry or anticipated during the&#xD;
             study period&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Gordon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>XOMA (US) LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

